Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics, a business unit of DSM Pharmaceutical products, has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Denmark-based Upfront Chromatography for pharmaceutical and other applications.
Subscribe to our email newsletter
As a result of the acquisition, DSM Biologics will gain all rights for the commercialisation of the Rhobust technology in various fields, including the pharma industry.
The Rhobust technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology.
Karen King, president of DSM Biologics, said: “The acquisition of the Rhobust technology is an important addition to the portfolio of DSM Biologics, a provider of technologies for the optimisation of biopharmaceutical manufacturing processes, in addition to world-class contract manufacturing services.
“The Rhobust technology combined with DSM’s proprietary XD technology will provide an integral package combining high titer, high yield processing with efficient downstream processing leading to lower manufacturing costs.”
Rolf Douwenga, vice president of global technology at DSM Biologics, said: “DSM Biologics develops new technologies to meet the challenges of future biopharmaceutical manufacturing. Our proprietary XD technology was a first step in yielding high density cell cultures.
“We have achieved up to 200 million cells/ml and titers up to 27 g/L for antibodies. This brings a real challenge to the downstream process; conventional process technology is of limited use here. With the Rhobust technology we can address this issue, and we are constantly broadening our technology portfolio for an even more effective biomanufacturing process.”